Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2005 1
2006 1
2008 1
2013 1
2014 1
2016 1
2017 4
2021 5
2022 3
2023 1

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of clinicodemographic characteristics and pattern of vascular involvement in 126 patients with Takayasu arteritis: a report from Iran and Turkey.
Tamartash Z, Javinani A, Pehlivan Y, Coskun BN, Yekta RA, Dalkilic E, Yağız B, Khavandgar N, Pournazari M, Hajiabbasi A, Sakar O, Zayeni H, Masoleh IS, Shakibi MR, Yazdi F, Mahmoudi M, Masoumi M, Mohammadzadegan AM, Sima F, Salehi S, Faezi ST, Jamshidi AR, Kavosi H. Tamartash Z, et al. Among authors: shakibi mr. Reumatismo. 2022 Dec 29;74(3). doi: 10.4081/reumatismo.2022.1487. Reumatismo. 2022. PMID: 36580066 Free article.
Assessment of Treatment Safety and Quality of Life in Patients Receiving Etanercept Biosimilar for Autoimmune Arthritis (ASQA): A Multicenter Post-marketing Surveillance Study.
Gharibdoost F, Salari AH, Salesi M, Ebrahimi Chaharom F, Mottaghi P, Hosseini M, Sahebari M, Nazarinia M, Mirfeizi Z, Shakibi M, Moussavi H, Karimifar M, Mowla K, Karimzadeh H, Anjidani N, Jamshidi A. Gharibdoost F, et al. Among authors: shakibi m. Adv Ther. 2021 Feb;38(2):1290-1300. doi: 10.1007/s12325-020-01611-8. Epub 2021 Jan 11. Adv Ther. 2021. PMID: 33432540
A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis.
Jamshidi A, Gharibdoost F, Vojdanian M, Soroosh SG, Soroush M, Ahmadzadeh A, Nazarinia MA, Mousavi M, Karimzadeh H, Shakibi MR, Rezaieyazdi Z, Sahebari M, Hajiabbasi A, Ebrahimi AA, Mahjourian N, Rashti AM. Jamshidi A, et al. Among authors: shakibi mr. Arthritis Res Ther. 2017 Jul 20;19(1):168. doi: 10.1186/s13075-017-1371-4. Arthritis Res Ther. 2017. PMID: 28728599 Free PMC article. Clinical Trial.
17 results